<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Finerenone</title><meta name="description" content="Finerenone , marketed under the brand name Kerendia among others, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal myocardial infarctions, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes,[8] and to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with symptomatic chronic heart failure and left..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="Kerendia"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Finerenone"/><meta property="og:title" content="Finerenone"/><meta property="og:description" content="Finerenone , marketed under the brand name Kerendia among others, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal myocardial infarctions, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes,[8] and to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with symptomatic chronic heart failure and left..."/><meta property="og:url" content="https://grokipedia.com/page/Finerenone"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Finerenone"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:12.900Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Finerenone"/><meta name="twitter:description" content="Finerenone , marketed under the brand name Kerendia among others, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal myocardial infarctions, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes,[8] and to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with symptomatic chronic heart failure and left..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="94d280535524ea8244865f0a743288cb-2f4a90b17d420534-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=94d280535524ea8244865f0a743288cb,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.9430789658096046,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#finerenone" class="transition-opacity hover:opacity-100 opacity-50">Finerenone</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#medical-uses" class="transition-opacity hover:opacity-100 opacity-50">Medical uses</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmacology" class="transition-opacity hover:opacity-100 opacity-50">Pharmacology</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pharmacokinetics" class="transition-opacity hover:opacity-100 opacity-50">Pharmacokinetics</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#adverse-effects" class="transition-opacity hover:opacity-100 opacity-50">Adverse effects</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#history" class="transition-opacity hover:opacity-100 opacity-50">History</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#legal-status" class="transition-opacity hover:opacity-100 opacity-50">Legal status</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#brand-names" class="transition-opacity hover:opacity-100 opacity-50">Brand names</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#research" class="transition-opacity hover:opacity-100 opacity-50">Research</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="finerenone" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Finerenone<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>













































































































<!-- -->
<span class="mb-4 block break-words text-[1em] leading-7"><strong>Finerenone</strong> , marketed under the brand name <strong>Kerendia</strong> among others, is a <span class="inline text-[1em] leading-7">medication</span> used to reduce the risk of kidney function decline, <span class="inline text-[1em] leading-7">kidney failure</span>, cardiovascular death, non-fatal <span class="inline text-[1em] leading-7">myocardial infarctions</span>, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_b1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> and to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with symptomatic chronic heart failure and left ventricular ejection fraction of 40% or greater.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup> Finerenone is a <span class="inline text-[1em] leading-7">non-steroidal</span> <span class="inline text-[1em] leading-7">mineralocorticoid receptor antagonist</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_j1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> It is taken <span class="inline text-[1em] leading-7">orally</span> (swallowed by mouth).</span>
<span class="mb-4 block break-words text-[1em] leading-7">Common side effects include abnormally high levels of potassium in the bloodstream, abnormally low levels of sodium in the bloodstream, and abnormally low blood pressure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_21qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Finerenone was approved for medical use in the United States in July 2021,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_22abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_32abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> for heart failure in the United States in July 2025,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_52abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup> and in the European Union in February 2022.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_72abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> The US <span class="inline text-[1em] leading-7">Food and Drug Administration</span> considers it to be a <span class="inline text-[1em] leading-7">first-in-class medication</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup></span>
<h2 id="medical-uses" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Medical uses<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">In the United States, finerenone is indicated to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_23abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> As of July 2025, it is also indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure with left ventricular ejection fraction (LVEF) â‰¥40%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In the European Union, finerenone is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_23qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<h2 id="pharmacology" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Pharmacology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Finerenone has less relative affinity to other steroid hormone receptors than currently available aldosterone antagonists such as eplerenone and spironolactone, which should result in fewer adverse effects like gynaecomastia, impotence, and low libido.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_24qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_34qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">This table compares inhibitory (blocking) concentrations (IC50, unit: nM) of three antimineralocorticoids. Mineralocorticoid receptor inhibition is responsible for the desired action of the drugs, whereas inhibition of the other receptors potentially leads to side effects. Lower values mean stronger inhibition.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_25abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>



































<div class="border-border-l1 overflow-x-auto rounded-lg border my-6 w-full"><table node="[object Object]" class="w-full border-collapse text-sm"><thead node="[object Object]" class="border-border-l1 border-b bg-surface-l1"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Receptor</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Spironolactone</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Eplerenone</span></th><th node="[object Object]" class="dark:text-fg-primary bg-gray-100 px-2 py-1 text-left align-top font-bold dark:bg-black"><span class="text-[1em] leading-7">Finerenone</span></th></tr></thead><tbody node="[object Object]" class="divide-border-l1 divide-y"><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Mineralocorticoid receptor</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">24</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">990</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">18</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Glucocorticoid receptor</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">2400</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">22,000</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">&gt;10,000</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Androgen receptor</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">77</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">21,200</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">&gt;10,000</span></td></tr><tr node="[object Object]" class="divide-border-l1 divide-x bg-surface-l1"><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">Progesterone receptor</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">740</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">31,200</span></td><td node="[object Object]" class="text-fg-primary px-2 py-1 align-top"><span class="text-[1em] leading-7">&gt;10,000</span></td></tr></tbody></table></div>
<span class="mb-4 block break-words text-[1em] leading-7">Finerenone acts as an antagonist to mineralocorticoid receptors harboring the S810L mutation, unlike other traditional inhibitors of mineralocorticoids such as spironolactone and eplerenone that incidentally act as agonists.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_26abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<h3 id="pharmacokinetics" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Pharmacokinetics<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Finerenone is administered orally and is rapidly absorbed, with a time to maximum concentration (Tmax) of approximately 1â€“2 hours. Its bioavailability is high, around 90â€“100%. The volume of distribution is about 50 L, and it is highly protein-bound (approximately 90â€“92%) primarily to albumin. Finerenone is extensively metabolized by cytochrome P450 enzymes, mainly CYP3A4 (about 90%) and to a lesser extent CYP2C8 (about 10%), with no active metabolites formed. Elimination occurs primarily via urine and feces as metabolites, with less than 1% excreted unchanged. The terminal half-life is approximately 2 hours, supporting once-daily dosing.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_27abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A meta-analysis of data from seven randomized controlled trials (13,783 participants) found a benefit to using finerenone in people with diabetic kidney disease and overt proteinuria.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_27qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup></span>
<h2 id="adverse-effects" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Adverse effects<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The most common adverse reactions reported in clinical trials were hyperkalemia (high potassium levels, occurring in 14% of patients), hypotension (low blood pressure, 4.6%), and hyponatremia (low sodium levels, 1.3%).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_28qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Finerenone may cause electrolyte imbalances, particularly hyperkalemia and hyponatremia. Symptoms of hyperkalemia include nausea, weakness, tingly feeling, chest pain, irregular heartbeats, and loss of movement.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_29abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup> Symptoms of hyponatremia may include headache, confusion, memory or thinking problems, weakness, and unsteadiness or feeling off balance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_49abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Hyperkalemia may lead to hospitalization (0.9% vs. 0.2% placebo) or treatment discontinuation (1.7% vs. 0.6% placebo). Serum potassium should be measured periodically during treatment, with more frequent monitoring recommended for at-risk patients (e.g., those with decreased kidney function or on potassium-elevating medications). Dose adjustments or withholding may be necessary if potassium levels exceed certain thresholds.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_29qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup></span>
<h2 id="history" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">History<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Finerenone was first described in 2012 as a nonsteroidal mineralocorticoid receptor antagonist developed by Bayer for cardiorenal diseases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Early clinical development included phase II trials. The ARTS-DN trial, published in 2015, evaluated finerenone in 823 patients with diabetic kidney disease, showing reductions in albuminuria.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup> The ARTS-HF trial, also reported in 2015, assessed finerenone versus eplerenone in 301 patients with heart failure and diabetes or chronic kidney disease, demonstrating similar efficacy with less hyperkalemia.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The efficacy of finerenone to improve kidney and heart outcomes was primarily evaluated in two phase III trials: FIDELIO-DKD and FIGARO-DKD. FIDELIO-DKD, a randomized, multicenter, double-blind, placebo-controlled study, enrolled adults with chronic kidney disease associated with type 2 diabetes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> In this study, 5,674 participants were randomly assigned to receive either finerenone or placebo.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The study compared the two groups for the number of participants whose disease progressed to a composite endpoint that included at least a 40% reduction in kidney function (defined by eGFR), progression to kidney failure, or kidney death.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> Results showed that 504 of the 2,833 participants who received finerenone had at least one of the events in the composite endpoint compared to 600 of the 2,841 participants who received placebo (hazard ratio 0.82; 95% CI 0.73-0.93; p=0.0014).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> A secondary cardiovascular composite endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) occurred in 367 finerenone participants versus 420 placebo (hazard ratio 0.86; 95% CI 0.75-0.99).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6cabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The confirmatory FIGARO-DKD trial, with 7,437 participants, showed similar benefits, with a composite kidney endpoint in 281 of 3,714 finerenone participants versus 361 of 3,723 placebo (hazard ratio 0.77; 95% CI 0.66-0.91).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup> A pooled analysis of both trials confirmed consistent effects on kidney and cardiovascular outcomes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4cqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The U.S. Food and Drug Administration (FDA) granted the application for finerenone priority review and fast track designations.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> The FDA approved Kerendia (finerenone) on July 9, 2021, for reducing the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> Approval was granted to Bayer HealthCare Pharmaceuticals.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_7dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In the European Union, finerenone was approved on February 24, 2022.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">On July 14, 2025, the FDA approved an expanded indication for Kerendia to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with symptomatic chronic heart failure and left ventricular ejection fraction of 40% or greater.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2eabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup></span>
<h2 id="legal-status" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Legal status<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Finerenone was approved for medical use in the United States in July 2021 and is available by prescription only.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup> It received approval in Australia in November 2021 and is classified as Schedule 4 (prescription only).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> In Canada, finerenone was approved in October 2022 and is available by prescription only.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In the European Union, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion in December 2021, recommending the granting of a marketing authorization for the medicinal product Kerendia, intended for the treatment of chronic kidney disease associated with type 2 diabetes in adults.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> Finerenone was approved for medical use in the European Union in February 2022 and is available by prescription only.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5fqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup></span>
<h2 id="brand-names" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Brand names<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">Finerenone is sold under the brand names Kerendia (primarily in the US, EU, and Japan) and Firialta (in select Asian countries such as Malaysia and the Philippines).</span>
<span class="mb-4 block break-words text-[1em] leading-7"><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_hqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup></span>
<h2 id="research" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Research<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">In the phase II ARTS-DN trial, finerenone reduced the urine albumin-to-creatinine ratio in patients with diabetic kidney disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The phase III FIDELIO-DKD and FIGARO-DKD trials, enrolling a total of more than 13,000 patients with type 2 diabetes and chronic kidney disease, were completed in 2020 and 2021, respectively. Both trials demonstrated that finerenone, compared to placebo, reduced the composite risk of chronic kidney disease progression, kidney failure, sustained decrease of â‰¥40% in eGFR, renal death, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3jqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Finerenone is under investigation for additional indications. In the phase III FINEARTS-HF trial, reported in 2024, finerenone reduced the risk of cardiovascular death and total heart failure events in patients with symptomatic heart failure with mildly reduced or preserved ejection fraction.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2labav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">As of 2025, ongoing phase III trials are evaluating finerenone in chronic kidney disease associated with type 1 diabetes, IgA nephropathy, and in combination with empagliflozin in type 2 diabetes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2mabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_nabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tga.gov.au/resources/resource/guidance/updates-prescribing-medicines-pregnancy-database" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Updates to the Prescribing Medicines in Pregnancy database&quot;</a>. <em>Therapeutic Goods Administration (TGA)</em>. 12 May 2022. Retrieved 13 May 2022.</span></div></li><li id="2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tga.gov.au/resources/auspmd/kerendia" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Kerendia APMDS&quot;</a>. <em>Therapeutic Goods Administration (TGA)</em>. 9 December 2021. Retrieved 12 June 2022.</span></div></li><li id="3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.tga.gov.au/auspar/auspar-finerenone" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;AusPAR: Finerenone&quot;</a>. <em>Therapeutic Goods Administration (TGA)</em>. 31 May 2022. Retrieved 12 June 2022.</span></div></li><li id="4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&amp;code=102100" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Kerendia Product information&quot;</a>. <em><span class="inline text-[1em] leading-7">Health Canada</span></em>. 25 April 2012. Retrieved 2 January 2023.</span></div></li><li id="5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?lang=en&amp;linkID=SBD00626&amp;lang=en" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Kerendia Summary Basis of Decision&quot;</a>. <em><span class="inline text-[1em] leading-7">Health Canada</span></em>. 23 October 2014. Retrieved 10 March 2023.</span></div></li><li id="6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://dhpp.hpfb-dgpsa.ca/dhpp/resource/102100" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Details for: Kerendia&quot;</a>. <em><span class="inline text-[1em] leading-7">Health Canada</span></em>. 22 November 2022. Retrieved 3 March 2024.</span></div></li><li id="7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc726765-5d5a-4d6e-b037-b847bda9fb7c" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Kerendia- finerenone tablet, film coated&quot;</a>. <em>DailyMed</em>. Retrieved 20 August 2021.</span></div></li><li id="8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20210709173129/https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;FDA Approves Drug for Chronic Kidney Disease&quot;</a>. <em>U.S.<span class="inline text-[1em] leading-7">Food and Drug Administration</span> (FDA)</em>. 9 July 2021. Archived from <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> on 9 July 2021. Retrieved 9 July 2021. <!-- --> This article incorporates text from this source, which is in the <span class="inline text-[1em] leading-7">public domain</span>.</span></div></li><li id="9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Kerendia EPAR&quot;</a>. <em><span class="inline text-[1em] leading-7">European Medicines Agency</span> (EMA)</em>. 14 December 2021. Retrieved 11 March 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215341Orig1s009ltr.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215341Orig1s009ltr.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215341Orig1s009ltr.pdf</a></span></div></li><li id="10" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.businesswire.com/news/home/20210709005441/en/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Bayer&#x27;s Kerendia (finerenone) Receives U.S. FDA Approval for Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes&quot;</a> (Press release). Bayer. 9 July 2021. Retrieved 9 July 2021 â€“ via Business Wire.</span></div></li><li id="11" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20221206210020/https://www.fda.gov/media/155227/download" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Advancing Health Through Innovation: New Drug Therapy Approvals 2021</a>. <em>U.S.<span class="inline text-[1em] leading-7">Food and Drug Administration</span> (FDA)</em> (Report). 13 May 2022. Archived from <a href="https://www.fda.gov/media/155227/download" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> (PDF) on 6 December 2022. Retrieved 22 January 2023. <!-- --> This article incorporates text from this source, which is in the <span class="inline text-[1em] leading-7">public domain</span>.</span></div></li><li id="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215341s009lbl.pdf" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215341s009lbl.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215341s009lbl.pdf</a></span></div></li><li id="12" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Ruilope LM, Tamargo J (April 2017). &quot;Renin-angiotensin system blockade: Finerenone&quot;. <em>Nephrologie &amp; Therapeutique</em>. <strong>13</strong> (Suppl 1): S47 â€“ S53. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.nephro.2017.02.003" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.nephro.2017.02.003</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/28577743" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">28577743</a>.</span></div></li><li id="13" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Pitt B, Anker SD, BÃ¶hm M, Gheorghiade M, KÃ¸ber L, Krum H, et al. (February 2015). <a href="https://deepblue.lib.umich.edu/bitstream/2027.42/110733/1/ejhf218.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease&quot;</a> (PDF). <em>European Journal of Heart Failure</em>. <strong>17</strong> (2): 224â€“32. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1002%2Fejhf.218" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1002/ejhf.218</a>. <span class="inline text-[1em] leading-7">hdl</span>:<a href="https://hdl.handle.net/2027.42%2F110733" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2027.42/110733</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25678098" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25678098</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:205781715" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">205781715</a>.<code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">{{cite journal}}</code>: CS1 maint: overridden setting (link)</span></div></li><li id="14" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">BÃ¤rfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-PÃ©rez S, Heckroth H, et al. (August 2012). &quot;Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases&quot;. <em>ChemMedChem</em>. <strong>7</strong> (8): 1385â€“1403. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1002%2Fcmdc.201200081" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1002/cmdc.201200081</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/22791416" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">22791416</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:36084480" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">36084480</a>.<code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">{{cite journal}}</code>: CS1 maint: overridden setting (link)</span></div></li><li id="15" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Amazit L, Le Billan F, Kolkhof P, Lamribet K, Viengchareun S, Fay MR, et al. (September 2015). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571943" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1&quot;</a>. <em>The Journal of Biological Chemistry</em>. <strong>290</strong> (36): 21876â€“89. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1074%2Fjbc.M115.657957" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1074/jbc.M115.657957</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571943" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">4571943</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/26203193" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">26203193</a>.<code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">{{cite journal}}</code>: CS1 maint: overridden setting (link)</span></div></li><li id="16" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Dutta D, Surana V, Bhattacharya S, Aggarwal S, Sharma M (Mayâ€“June 2022). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555385" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Efficacy and Safety of Novel Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in the Management of Diabetic Kidney Disease: A Meta-analysis&quot;</a>. <em>Indian J Endocrinol Metab</em>. <strong>26</strong> (3): 198â€“205. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.4103%2Fijem.ijem_376_21" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.4103/ijem.ijem_376_21</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555385" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">9555385</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/36248038" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">36248038</a>.</span></div></li><li id="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc726765-5d5a-4d6e-b037-b847bda9fb7c" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc726765-5d5a-4d6e-b037-b847bda9fb7c" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc726765-5d5a-4d6e-b037-b847bda9fb7c</a></span></div></li><li id="https://www.drugs.com/mtm/finerenone.html" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.drugs.com/mtm/finerenone.html" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.drugs.com/mtm/finerenone.html</a></span></div></li><li id="21" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. (September 2015). <a href="https://doi.org/10.1001%2Fjama.2015.10081" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial&quot;</a>. <em>JAMA</em>. <strong>314</strong> (9): 884â€“94. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1001%2Fjama.2015.10081" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1001/jama.2015.10081</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/26325557" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">26325557</a>.<code class="text-fg-solar bg-fg-solar-opaque break-all rounded px-2 align-middle font-mono text-sm" node="[object Object]">{{cite journal}}</code>: CS1 maint: overridden setting (link)</span></div></li><li id="22" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Clinical trial number <em><a href="https://www.clinicaltrials.gov/show/NCT02540993" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">NCT02540993</a></em> for &quot;Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease (FIDELIO-DKD)&quot; at <span class="inline text-[1em] leading-7">ClinicalTrials.gov</span></span></div></li><li id="23" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Clinical trial number <em><a href="https://www.clinicaltrials.gov/show/NCT02545049" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">NCT02545049</a></em> for &quot;Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease (FIGARO-DKD)&quot; at <span class="inline text-[1em] leading-7">ClinicalTrials.gov</span></span></div></li><li id="20" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bayer.com/media/en-us/finerenone-meets-primary-endpoint-in-phase-iii-finearts-hf-cardiovascular-outcomes-study-in-patients-with-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Finerenone meets primary endpoint in Phase III FINEARTS-HF cardiovascular outcomes study in patients with heart failure with mildly reduced or preserved ejection fraction&quot;</a>. <em>Bayer</em> (Press release). 5 August 2024. Retrieved 15 October 2024.</span></div></li><li id="18" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20221028161708/https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Kerendia: Pending EC decision&quot;</a>. <em><span class="inline text-[1em] leading-7">European Medicines Agency</span> (EMA)</em>. 16 December 2021. Archived from <a href="https://www.ema.europa.eu/en/medicines/human/summaries-opinion/kerendia" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> on 28 October 2022. Retrieved 18 December 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</span></div></li><li id="19" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://ec.europa.eu/health/documents/community-register/html/h1616.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Kerendia Product information&quot;</a>. <em>Union Register of medicinal products</em>. Retrieved 3 March 2023.</span></div></li><li id="https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease</a></span></div></li><li id="https://www.bayer.com/media/en-us/bayer-receives-approval-in-japan-for-kerendiatm-finerenone-a-new-treatment-for-adults-with-chronic-kidney-disease-and-type-2-diabetes/" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.bayer.com/media/en-us/bayer-receives-approval-in-japan-for-kerendiatm-finerenone-a-new-treatment-for-adults-with-chronic-kidney-disease-and-type-2-diabetes/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.bayer.com/media/en-us/bayer-receives-approval-in-japan-for-kerendiatm-finerenone-a-new-treatment-for-adults-with-chronic-kidney-disease-and-type-2-diabetes/</a></span></div></li><li id="https://www.firialta.my/en" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.firialta.my/en" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.firialta.my/en</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa2025845" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2025845" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa2025845</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa2110956" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2110956" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa2110956</a></span></div></li><li id="https://www.nejm.org/doi/abs/10.1056/NEJMoa2407107" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/abs/10.1056/NEJMoa2407107" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/abs/10.1056/NEJMoa2407107</a></span></div></li><li id="https://clinicaltrials.gov/study/NCT07056595" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://clinicaltrials.gov/study/NCT07056595" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://clinicaltrials.gov/study/NCT07056595</a></span></div></li><li id="https://www.nejm.org/doi/full/10.1056/NEJMoa2410659" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2410659" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.nejm.org/doi/full/10.1056/NEJMoa2410659</a></span></div></li></ol></div><div class="text-fg-secondary text-xs [&amp;_*]:mb-2"><hr class="border-border-l1 my-8 rounded-sm border-t"/>
<span class="mb-4 block break-words text-[1em] leading-7">The content is adapted from <a href="https://en.wikipedia.org/wiki/Finerenone" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Wikipedia</a>, licensed under Creative Commons Attribution-ShareAlike 4.0 License.</span></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl" id="_R_" async=""></script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl\"}]\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Finerenone\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Finerenone\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Finerenone\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T3790,"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"# Finerenone\n\n| Attribute | Details |\n|-----------|---------|\n| Trade names | [Kerendia](Drug_nomenclature#Trade_names \"Drug nomenclature\") |\n| Other names | BAY 94-8862 |\n| AHFS/Drugs.com | [Monograph](https://www.drugs.com/monograph/finerenone.html) |\n| MedlinePlus | [a621038](https://medlineplus.gov/druginfo/meds/a621038.html) |\n| License data | US [DailyMed](DailyMed \"DailyMed\"): [Finerenone](https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all\u0026query=Finerenone) |\n| Pregnancy category | AU: D[1][2] |\n| Routes of administration | [Oral](Oral_administration \"Oral administration\") |\n| Drug class | [Nonsteroidal mineralocorticoid receptor antagonist](Mineralocorticoid_receptor_antagonist \"Mineralocorticoid receptor antagonist\") |\n| ATC code | [C03DA05](ATC_code_C03 \"ATC code C03\") ([WHO](https://www.whocc.no/atc_ddd_index/?code=C03DA05)) |\n| Legal status | AU: [S4](Standard_for_the_Uniform_Scheduling_of_Medicines_and_Poisons#Schedule_4 \"Standard for the Uniform Scheduling of Medicines and Poisons\") (Prescription only)[2][3]\u003cbr\u003eCA: [ â„ž-only](Prescription_drug \"Prescription drug\")[4][5][6]\u003cbr\u003eUS: [â„ž-only](Prescription_drug \"Prescription drug\")[7][8]\u003cbr\u003eEU: Rx-only[9] |\n| IUPAC name | (4 *S*)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide |\n| CAS Number | [1050477-31-0](https://commonchemistry.cas.org/detail?cas_rn=1050477-31-0) |\n| PubChem CID | [60150535](https://pubchem.ncbi.nlm.nih.gov/compound/60150535) |\n| DrugBank | [DB16165](https://www.drugbank.ca/drugs/DB16165) |\n| ChemSpider | [28669387](https://www.chemspider.com/Chemical-Structure.28669387.html) |\n| UNII | [DE2O63YV8R](https://precision.fda.gov/uniisearch/srs/unii/DE2O63YV8R) |\n| KEGG | [D10633](https://www.kegg.jp/entry/D10633) |\n| ChEMBL | [ChEMBL2181927](https://www.ebi.ac.uk/chembl/explore/compound/ChEMBL2181927) |\n| CompTox Dashboard (EPA) | [DTXSID10146928](https://comptox.epa.gov/dashboard/chemical/details/DTXSID10146928) |\n| ECHA InfoCard | [100.247.614](https://echa.europa.eu/substance-information/-/substanceinfo/100.247.614) |\n| Formula | C\u003csub\u003e21\u003c/sub\u003eH\u003csub\u003e22\u003c/sub\u003eN\u003csub\u003e4\u003c/sub\u003eO\u003csub\u003e3\u003c/sub\u003e |\n| Molar mass | 378.432 gÂ·mol\u003csup\u003eâˆ’1\u003c/sup\u003e |\n| 3D model (JSmol) | [Interactive image](https://chemapps.stolaf.edu/jmol/jmol.php?model=NC%28%3DO%29C1%3DC%28C%29Nc2c%28C%29cnc%28OCC%29c2%5BC%40%40H%5D1c3ccc%28C%23N%29cc3OC) |\n| SMILES | NC(=O)C1=C(C)Nc2c(C)cnc(OCC)c2[C@@H]1c3ccc(C#N)cc3OC |\n| InChI | InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1\u003cbr\u003eKey: BTBHLEZXCOBLCY-QGZVFWFLSA-N |\n\n**Finerenone** , marketed under the brand name **Kerendia** among others, is a [medication](Medication \"Medication\") used to reduce the risk of kidney function decline, [kidney failure](Kidney_failure \"Kidney failure\"), cardiovascular death, non-fatal [myocardial infarctions](Myocardial_infarction \"Myocardial infarction\"), and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes,[8] and to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with symptomatic chronic heart failure and left ventricular ejection fraction of 40% or greater.[](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215341Orig1s009ltr.pdf) Finerenone is a [non-steroidal](Non-steroidal \"Non-steroidal\") [mineralocorticoid receptor antagonist](Mineralocorticoid_receptor_antagonist \"Mineralocorticoid receptor antagonist\").[7] It is taken [orally](Oral_administration \"Oral administration\") (swallowed by mouth). \n\nCommon side effects include abnormally high levels of potassium in the bloodstream, abnormally low levels of sodium in the bloodstream, and abnormally low blood pressure.[8]\n\nFinerenone was approved for medical use in the United States in July 2021,[8][10] for heart failure in the United States in July 2025,[](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215341Orig1s009ltr.pdf) and in the European Union in February 2022.[9] The US [Food and Drug Administration](Food_and_Drug_Administration \"Food and Drug Administration\") considers it to be a [first-in-class medication](First-in-class_medication \"First-in-class medication\").[11]\n# Finerenone\n\n## Medical uses\n\nIn the United States, finerenone is indicated to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes.[8] As of July 2025, it is also indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure with left ventricular ejection fraction (LVEF) â‰¥40%.[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215341s009lbl.pdf)\n\nIn the European Union, finerenone is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.[9]\n## Pharmacology\n\nFinerenone has less relative affinity to other steroid hormone receptors than currently available aldosterone antagonists such as eplerenone and spironolactone, which should result in fewer adverse effects like gynaecomastia, impotence, and low libido.[12][13]\n\nThis table compares inhibitory (blocking) concentrations (IC50, unit: nM) of three antimineralocorticoids. Mineralocorticoid receptor inhibition is responsible for the desired action of the drugs, whereas inhibition of the other receptors potentially leads to side effects. Lower values mean stronger inhibition.[14]\n\n| Receptor                  | Spironolactone | Eplerenone | Finerenone |\n|---------------------------|----------------|------------|------------|\n| Mineralocorticoid receptor | 24             | 990        | 18         |\n| Glucocorticoid receptor   | 2400           | 22,000     | \u003e10,000    |\n| Androgen receptor         | 77             | 21,200     | \u003e10,000    |\n| Progesterone receptor     | 740            | 31,200     | \u003e10,000    |\n\nFinerenone acts as an antagonist to mineralocorticoid receptors harboring the S810L mutation, unlike other traditional inhibitors of mineralocorticoids such as spironolactone and eplerenone that incidentally act as agonists.[15]\n\n### Pharmacokinetics\n\nFinerenone is administered orally and is rapidly absorbed, with a time to maximum concentration (Tmax) of approximately 1â€“2 hours. Its bioavailability is high, around 90â€“100%. The volume of distribution is about 50 L, and it is highly protein-bound (approximately 90â€“92%) primarily to albumin. Finerenone is extensively metabolized by cytochrome P450 enzymes, mainly CYP3A4 (about 90%) and to a lesser extent CYP2C8 (about 10%), with no active metabolites formed. Elimination occurs primarily via urine and feces as metabolites, with less than 1% excreted unchanged. The terminal half-life is approximately 2 hours, supporting once-daily dosing.[7]\n\nA meta-analysis of data from seven randomized controlled trials (13,783 participants) found a benefit to using finerenone in people with diabetic kidney disease and overt proteinuria.[16]\n## Adverse effects\n\nThe most common adverse reactions reported in clinical trials were hyperkalemia (high potassium levels, occurring in 14% of patients), hypotension (low blood pressure, 4.6%), and hyponatremia (low sodium levels, 1.3%).[](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc726765-5d5a-4d6e-b037-b847bda9fb7c)\n\nFinerenone may cause electrolyte imbalances, particularly hyperkalemia and hyponatremia. Symptoms of hyperkalemia include nausea, weakness, tingly feeling, chest pain, irregular heartbeats, and loss of movement.[](https://www.drugs.com/mtm/finerenone.html) Symptoms of hyponatremia may include headache, confusion, memory or thinking problems, weakness, and unsteadiness or feeling off balance.[](https://www.drugs.com/mtm/finerenone.html)\n\nHyperkalemia may lead to hospitalization (0.9% vs. 0.2% placebo) or treatment discontinuation (1.7% vs. 0.6% placebo). Serum potassium should be measured periodically during treatment, with more frequent monitoring recommended for at-risk patients (e.g., those with decreased kidney function or on potassium-elevating medications). Dose adjustments or withholding may be necessary if potassium levels exceed certain thresholds.[](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc726765-5d5a-4d6e-b037-b847bda9fb7c)\n# Finerenone\n\n## History\n\nFinerenone was first described in 2012 as a nonsteroidal mineralocorticoid receptor antagonist developed by Bayer for cardiorenal diseases.[14]\n\nEarly clinical development included phase II trials. The ARTS-DN trial, published in 2015, evaluated finerenone in 823 patients with diabetic kidney disease, showing reductions in albuminuria.[21] The ARTS-HF trial, also reported in 2015, assessed finerenone versus eplerenone in 301 patients with heart failure and diabetes or chronic kidney disease, demonstrating similar efficacy with less hyperkalemia.[13]\n\nThe efficacy of finerenone to improve kidney and heart outcomes was primarily evaluated in two phase III trials: FIDELIO-DKD and FIGARO-DKD. FIDELIO-DKD, a randomized, multicenter, double-blind, placebo-controlled study, enrolled adults with chronic kidney disease associated with type 2 diabetes.[8][22] In this study, 5,674 participants were randomly assigned to receive either finerenone or placebo.[8]\n\nThe study compared the two groups for the number of participants whose disease progressed to a composite endpoint that included at least a 40% reduction in kidney function (defined by eGFR), progression to kidney failure, or kidney death.[8] Results showed that 504 of the 2,833 participants who received finerenone had at least one of the events in the composite endpoint compared to 600 of the 2,841 participants who received placebo (hazard ratio 0.82; 95% CI 0.73-0.93; p=0.0014).[8] A secondary cardiovascular composite endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure) occurred in 367 finerenone participants versus 420 placebo (hazard ratio 0.86; 95% CI 0.75-0.99).[8]\n\nThe confirmatory FIGARO-DKD trial, with 7,437 participants, showed similar benefits, with a composite kidney endpoint in 281 of 3,714 finerenone participants versus 361 of 3,723 placebo (hazard ratio 0.77; 95% CI 0.66-0.91).[23] A pooled analysis of both trials confirmed consistent effects on kidney and cardiovascular outcomes.[9]\n\nThe U.S. Food and Drug Administration (FDA) granted the application for finerenone priority review and fast track designations.[8] The FDA approved Kerendia (finerenone) on July 9, 2021, for reducing the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes.[8][10] Approval was granted to Bayer HealthCare Pharmaceuticals.[8]\n\nIn the European Union, finerenone was approved on February 24, 2022.[9]\n\nOn July 14, 2025, the FDA approved an expanded indication for Kerendia to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with symptomatic chronic heart failure and left ventricular ejection fraction of 40% or greater.[20]\n## Legal status\n\nFinerenone was approved for medical use in the United States in July 2021 and is available by prescription only.[8] It received approval in Australia in November 2021 and is classified as Schedule 4 (prescription only).[2] In Canada, finerenone was approved in October 2022 and is available by prescription only.[4]\n\nIn the European Union, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion in December 2021, recommending the granting of a marketing authorization for the medicinal product Kerendia, intended for the treatment of chronic kidney disease associated with type 2 diabetes in adults.[18] Finerenone was approved for medical use in the European Union in February 2022 and is available by prescription only.[9][19]\n## Brand names\n\nFinerenone is sold under the brand names Kerendia (primarily in the US, EU, and Japan) and Firialta (in select Asian countries such as Malaysia and the Philippines).\n\n[](https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease)\n\n[](https://www.bayer.com/media/en-us/bayer-receives-approval-in-japan-for-kerendiatm-finerenone-a-new-treatment-for-adults-with-chronic-kidney-disease-and-type-2-diabetes/)\n\n[](https://www.firialta.my/en)\n## Research\n\nIn the phase II ARTS-DN trial, finerenone reduced the urine albumin-to-creatinine ratio in patients with diabetic kidney disease.[21]\n\nThe phase III FIDELIO-DKD and FIGARO-DKD trials, enrolling a total of more than 13,000 patients with type 2 diabetes and chronic kidney disease, were completed in 2020 and 2021, respectively. Both trials demonstrated that finerenone, compared to placebo, reduced the composite risk of chronic kidney disease progression, kidney failure, sustained decrease of â‰¥40% in eGFR, renal death, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure.[22][23]\n\n[](https://www.nejm.org/doi/full/10.1056/NEJMoa2025845)\n\n[](https://www.nejm.org/doi/full/10.1056/NEJMoa2110956)\n\nFinerenone is under investigation for additional indications. In the phase III FINEARTS-HF trial, reported in 2024, finerenone reduced the risk of cardiovascular death and total heart failure events in patients with symptomatic heart failure with mildly reduced or preserved ejection fraction.[20]\n\n[](https://www.nejm.org/doi/abs/10.1056/NEJMoa2407107)\n\nAs of 2025, ongoing phase III trials are evaluating finerenone in chronic kidney disease associated with type 1 diabetes, IgA nephropathy, and in combination with empagliflozin in type 2 diabetes.[16]\n\n[](https://clinicaltrials.gov/study/NCT07056595)\n\n[](https://www.nejm.org/doi/full/10.1056/NEJMoa2410659)"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761884039128,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"** [\\\"Updates to the Prescribing Medicines in Pregnancy database\\\"](https://www.tga.gov.au/resources/resource/guidance/updates-prescribing-medicines-pregnancy-database). _Therapeutic Goods Administration (TGA)_. 12 May 2022. Retrieved 13 May 2022.\",\"description\":\"1. **^** [\\\"Updates to the Prescribing Medicines in Pregnancy database\\\"](https://www.tga.gov.au/resources/resource/guidance/updates-prescribing-medicines-pregnancy-database). _Therapeutic Goods Administration (TGA)_. 12 May 2022. Retrieved 13 May 2022.\",\"url\":\"https://www.tga.gov.au/resources/resource/guidance/updates-prescribing-medicines-pregnancy-database\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"_**a**_ _**b**_ [\\\"Kerendia APMDS\\\"](https://www.tga.gov.au/resources/auspmd/kerendia). _Therapeutic Goods Administration (TGA)_. 9 December 2021. Retrieved 12 June 2022.\",\"description\":\"2. ^ _**a**_ _**b**_ [\\\"Kerendia APMDS\\\"](https://www.tga.gov.au/resources/auspmd/kerendia). _Therapeutic Goods Administration (TGA)_. 9 December 2021. Retrieved 12 June 2022.\",\"url\":\"https://www.tga.gov.au/resources/auspmd/kerendia\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"** [\\\"AusPAR: Finerenone\\\"](https://www.tga.gov.au/auspar/auspar-finerenone). _Therapeutic Goods Administration (TGA)_. 31 May 2022. Retrieved 12 June 2022.\",\"description\":\"3. **^** [\\\"AusPAR: Finerenone\\\"](https://www.tga.gov.au/auspar/auspar-finerenone). _Therapeutic Goods Administration (TGA)_. 31 May 2022. Retrieved 12 June 2022.\",\"url\":\"https://www.tga.gov.au/auspar/auspar-finerenone\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"** [\\\"Kerendia Product information\\\"](https://health-products.canada.ca/dpd-bdpp/info.do?lang=en\u0026code=102100). _[Health Canada](Health_Canada \\\"Health Canada\\\")_. 25 April 2012. Retrieved 2 January 2023.\",\"description\":\"4. **^** [\\\"Kerendia Product information\\\"](https://health-products.canada.ca/dpd-bdpp/info.do?lang=en\u0026code=102100). _[Health Canada](Health_Canada \\\"Health Canada\\\")_. 25 April 2012. Retrieved 2 January 2023.\",\"url\":\"https://health-products.canada.ca/dpd-bdpp/info.do?lang=en\u0026code=102100\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"** [\\\"Kerendia Summary Basis of Decision\\\"](https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?lang=en\u0026linkID=SBD00626\u0026lang=en). _[Health Canada](Health_Canada \\\"Health Canada\\\")_. 23 October 2014. Retrieved 10 March 2023.\",\"description\":\"5. **^** [\\\"Kerendia Summary Basis of Decision\\\"](https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?lang=en\u0026linkID=SBD00626\u0026lang=en). _[Health Canada](Health_Canada \\\"Health Canada\\\")_. 23 October 2014. Retrieved 10 March 2023.\",\"url\":\"https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?lang=en\u0026linkID=SBD00626\u0026lang=en\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"** [\\\"Details for: Kerendia\\\"](https://dhpp.hpfb-dgpsa.ca/dhpp/resource/102100). _[Health Canada](Health_Canada \\\"Health Canada\\\")_. 22 November 2022. Retrieved 3 March 2024.\",\"description\":\"6. **^** [\\\"Details for: Kerendia\\\"](https://dhpp.hpfb-dgpsa.ca/dhpp/resource/102100). _[Health Canada](Health_Canada \\\"Health Canada\\\")_. 22 November 2022. Retrieved 3 March 2024.\",\"url\":\"https://dhpp.hpfb-dgpsa.ca/dhpp/resource/102100\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"_**a**_ _**b**_ [\\\"Kerendia- finerenone tablet, film coated\\\"](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc726765-5d5a-4d6e-b037-b847bda9fb7c). _DailyMed_. Retrieved 20 August 2021.\",\"description\":\"7. ^ _**a**_ _**b**_ [\\\"Kerendia- finerenone tablet, film coated\\\"](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc726765-5d5a-4d6e-b037-b847bda9fb7c). _DailyMed_. Retrieved 20 August 2021.\",\"url\":\"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc726765-5d5a-4d6e-b037-b847bda9fb7c\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ [\\\"FDA Approves Drug for Chronic Kidney Disease\\\"](https://web.archive.org/web/20210709173129/https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease). _U.S.[Food and Drug Administration](Food_and_Drug_Administration \\\"Food and Drug Administration\\\") (FDA)_. 9 July 2021. Archived from [the original](https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease) on 9 July 2021. Retrieved 9 July 2021. ![Public Domain](./_assets_/PD-icon.svg.png) This article incorporates text from this source, which is in the [public domain](Public_domain \\\"Public domain\\\").\",\"description\":\"8. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ [\\\"FDA Approves Drug for Chronic Kidney Disease\\\"](https://web.archive.org/web/20210709173129/https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease). _U.S.[Food and Drug Administration](Food_and_Drug_Administration \\\"Food and Drug Administration\\\") (FDA)_. 9 July 2021. Archived from [the original](https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease) on 9 July 2021. Retrieved 9 July 2021. ![Public Domain](./_assets_/PD-icon.svg.png) This article incorporates text from this source, which is in the [public domain](Public_domain \\\"Public domain\\\").\",\"url\":\"https://web.archive.org/web/20210709173129/https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ [\\\"Kerendia EPAR\\\"](https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia). _[European Medicines Agency](European_Medicines_Agency \\\"European Medicines Agency\\\") (EMA)_. 14 December 2021. Retrieved 11 March 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.\",\"description\":\"9. ^ _**a**_ _**b**_ _**c**_ _**d**_ [\\\"Kerendia EPAR\\\"](https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia). _[European Medicines Agency](European_Medicines_Agency \\\"European Medicines Agency\\\") (EMA)_. 14 December 2021. Retrieved 11 March 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.\",\"url\":\"https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"** [\\\"Bayer's Kerendia (finerenone) Receives U.S. FDA Approval for Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes\\\"](https://www.businesswire.com/news/home/20210709005441/en/) (Press release). Bayer. 9 July 2021. Retrieved 9 July 2021 â€“ via Business Wire.\",\"description\":\"10. **^** [\\\"Bayer's Kerendia (finerenone) Receives U.S. FDA Approval for Treatment of Patients with Chronic Kidney Disease Associated with Type 2 Diabetes\\\"](https://www.businesswire.com/news/home/20210709005441/en/) (Press release). Bayer. 9 July 2021. Retrieved 9 July 2021 â€“ via Business Wire.\",\"url\":\"https://www.businesswire.com/news/home/20210709005441/en/\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"** [Advancing Health Through Innovation: New Drug Therapy Approvals 2021](https://web.archive.org/web/20221206210020/https://www.fda.gov/media/155227/download). _U.S.[Food and Drug Administration](Food_and_Drug_Administration \\\"Food and Drug Administration\\\") (FDA)_ (Report). 13 May 2022. Archived from [the original](https://www.fda.gov/media/155227/download) (PDF) on 6 December 2022. Retrieved 22 January 2023. ![Public Domain](./_assets_/PD-icon.svg.png) This article incorporates text from this source, which is in the [public domain](Public_domain \\\"Public domain\\\").\",\"description\":\"11. **^** [Advancing Health Through Innovation: New Drug Therapy Approvals 2021](https://web.archive.org/web/20221206210020/https://www.fda.gov/media/155227/download). _U.S.[Food and Drug Administration](Food_and_Drug_Administration \\\"Food and Drug Administration\\\") (FDA)_ (Report). 13 May 2022. Archived from [the original](https://www.fda.gov/media/155227/download) (PDF) on 6 December 2022. Retrieved 22 January 2023. ![Public Domain](./_assets_/PD-icon.svg.png) This article incorporates text from this source, which is in the [public domain](Public_domain \\\"Public domain\\\").\",\"url\":\"https://web.archive.org/web/20221206210020/https://www.fda.gov/media/155227/download\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"** Ruilope LM, Tamargo J (April 2017). \\\"Renin-angiotensin system blockade: Finerenone\\\". _Nephrologie \u0026 Therapeutique_. **13** (Suppl 1): S47 â€“ S53. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.nephro.2017.02.003](https://doi.org/10.1016%2Fj.nephro.2017.02.003). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28577743](https://pubmed.ncbi.nlm.nih.gov/28577743).\",\"description\":\"12. **^** Ruilope LM, Tamargo J (April 2017). \\\"Renin-angiotensin system blockade: Finerenone\\\". _Nephrologie \u0026 Therapeutique_. **13** (Suppl 1): S47 â€“ S53. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.nephro.2017.02.003](https://doi.org/10.1016%2Fj.nephro.2017.02.003). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [28577743](https://pubmed.ncbi.nlm.nih.gov/28577743).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"** Pitt B, Anker SD, BÃ¶hm M, Gheorghiade M, KÃ¸ber L, Krum H, et al. (February 2015). [\\\"Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease\\\"](https://deepblue.lib.umich.edu/bitstream/2027.42/110733/1/ejhf218.pdf) (PDF). _European Journal of Heart Failure_. **17** (2): 224â€“32\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/ejhf.218](https://doi.org/10.1002%2Fejhf.218). [hdl](Hdl_\\\\(identifier\\\\) \\\"Hdl \\\\(identifier\\\\)\\\"):[2027.42/110733](https://hdl.handle.net/2027.42%2F110733). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25678098](https://pubmed.ncbi.nlm.nih.gov/25678098). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [205781715](https://api.semanticscholar.org/CorpusID:205781715).`{{cite journal}}`: CS1 maint: overridden setting (link)\",\"description\":\"13. **^** Pitt B, Anker SD, BÃ¶hm M, Gheorghiade M, KÃ¸ber L, Krum H, et al. (February 2015). [\\\"Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease\\\"](https://deepblue.lib.umich.edu/bitstream/2027.42/110733/1/ejhf218.pdf) (PDF). _European Journal of Heart Failure_. **17** (2): 224â€“32\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/ejhf.218](https://doi.org/10.1002%2Fejhf.218). [hdl](Hdl_\\\\(identifier\\\\) \\\"Hdl \\\\(identifier\\\\)\\\"):[2027.42/110733](https://hdl.handle.net/2027.42%2F110733). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25678098](https://pubmed.ncbi.nlm.nih.gov/25678098). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [205781715](https://api.semanticscholar.org/CorpusID:205781715).`{{cite journal}}`: CS1 maint: overridden setting (link)\",\"url\":\"https://deepblue.lib.umich.edu/bitstream/2027.42/110733/1/ejhf218.pdf\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"** BÃ¤rfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-PÃ©rez S, Heckroth H, et al. (August 2012). \\\"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases\\\". _ChemMedChem_. **7** (8): 1385â€“1403\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/cmdc.201200081](https://doi.org/10.1002%2Fcmdc.201200081). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22791416](https://pubmed.ncbi.nlm.nih.gov/22791416). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [36084480](https://api.semanticscholar.org/CorpusID:36084480).`{{cite journal}}`: CS1 maint: overridden setting (link)\",\"description\":\"14. **^** BÃ¤rfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-PÃ©rez S, Heckroth H, et al. (August 2012). \\\"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases\\\". _ChemMedChem_. **7** (8): 1385â€“1403\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/cmdc.201200081](https://doi.org/10.1002%2Fcmdc.201200081). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [22791416](https://pubmed.ncbi.nlm.nih.gov/22791416). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [36084480](https://api.semanticscholar.org/CorpusID:36084480).`{{cite journal}}`: CS1 maint: overridden setting (link)\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"** Amazit L, Le Billan F, Kolkhof P, Lamribet K, Viengchareun S, Fay MR, et al. (September 2015). [\\\"Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571943). _The Journal of Biological Chemistry_. **290** (36): 21876â€“89\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1074/jbc.M115.657957](https://doi.org/10.1074%2Fjbc.M115.657957). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4571943](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571943). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26203193](https://pubmed.ncbi.nlm.nih.gov/26203193).`{{cite journal}}`: CS1 maint: overridden setting (link)\",\"description\":\"15. **^** Amazit L, Le Billan F, Kolkhof P, Lamribet K, Viengchareun S, Fay MR, et al. (September 2015). [\\\"Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571943). _The Journal of Biological Chemistry_. **290** (36): 21876â€“89\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1074/jbc.M115.657957](https://doi.org/10.1074%2Fjbc.M115.657957). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [4571943](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571943). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26203193](https://pubmed.ncbi.nlm.nih.gov/26203193).`{{cite journal}}`: CS1 maint: overridden setting (link)\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571943\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"** Dutta D, Surana V, Bhattacharya S, Aggarwal S, Sharma M (Mayâ€“June 2022). [\\\"Efficacy and Safety of Novel Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in the Management of Diabetic Kidney Disease: A Meta-analysis\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555385). _Indian J Endocrinol Metab_. **26** (3): 198â€“205\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4103/ijem.ijem_376_21](https://doi.org/10.4103%2Fijem.ijem_376_21). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [9555385](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555385). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [36248038](https://pubmed.ncbi.nlm.nih.gov/36248038).\",\"description\":\"16. **^** Dutta D, Surana V, Bhattacharya S, Aggarwal S, Sharma M (Mayâ€“June 2022). [\\\"Efficacy and Safety of Novel Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in the Management of Diabetic Kidney Disease: A Meta-analysis\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555385). _Indian J Endocrinol Metab_. **26** (3): 198â€“205\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.4103/ijem.ijem_376_21](https://doi.org/10.4103%2Fijem.ijem_376_21). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [9555385](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555385). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [36248038](https://pubmed.ncbi.nlm.nih.gov/36248038).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555385\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"_**a**_ _**b**_ _**c**_ [\\\"Finerenone Uses, Side Effects \u0026 Warnings\\\"](https://www.drugs.com/mtm/finerenone.html). _Drugs.com_. Retrieved 11 June 2022.\",\"description\":\"17. ^ _**a**_ _**b**_ _**c**_ [\\\"Finerenone Uses, Side Effects \u0026 Warnings\\\"](https://www.drugs.com/mtm/finerenone.html). _Drugs.com_. Retrieved 11 June 2022.\",\"url\":\"https://www.drugs.com/mtm/finerenone.html\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"** [\\\"Kerendia: Pending EC decision\\\"](https://web.archive.org/web/20221028161708/https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia). _[European Medicines Agency](European_Medicines_Agency \\\"European Medicines Agency\\\") (EMA)_. 16 December 2021. Archived from [the original](https://www.ema.europa.eu/en/medicines/human/summaries-opinion/kerendia) on 28 October 2022. Retrieved 18 December 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.\",\"description\":\"18. **^** [\\\"Kerendia: Pending EC decision\\\"](https://web.archive.org/web/20221028161708/https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia). _[European Medicines Agency](European_Medicines_Agency \\\"European Medicines Agency\\\") (EMA)_. 16 December 2021. Archived from [the original](https://www.ema.europa.eu/en/medicines/human/summaries-opinion/kerendia) on 28 October 2022. Retrieved 18 December 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.\",\"url\":\"https://web.archive.org/web/20221028161708/https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"** [\\\"Kerendia Product information\\\"](https://ec.europa.eu/health/documents/community-register/html/h1616.htm). _Union Register of medicinal products_. Retrieved 3 March 2023.\",\"description\":\"19. **^** [\\\"Kerendia Product information\\\"](https://ec.europa.eu/health/documents/community-register/html/h1616.htm). _Union Register of medicinal products_. Retrieved 3 March 2023.\",\"url\":\"https://ec.europa.eu/health/documents/community-register/html/h1616.htm\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"** [\\\"Finerenone meets primary endpoint in Phase III FINEARTS-HF cardiovascular outcomes study in patients with heart failure with mildly reduced or preserved ejection fraction\\\"](https://www.bayer.com/media/en-us/finerenone-meets-primary-endpoint-in-phase-iii-finearts-hf-cardiovascular-outcomes-study-in-patients-with-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction/). _Bayer_ (Press release). 5 August 2024. Retrieved 15 October 2024.\",\"description\":\"20. **^** [\\\"Finerenone meets primary endpoint in Phase III FINEARTS-HF cardiovascular outcomes study in patients with heart failure with mildly reduced or preserved ejection fraction\\\"](https://www.bayer.com/media/en-us/finerenone-meets-primary-endpoint-in-phase-iii-finearts-hf-cardiovascular-outcomes-study-in-patients-with-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction/). _Bayer_ (Press release). 5 August 2024. Retrieved 15 October 2024.\",\"url\":\"https://www.bayer.com/media/en-us/finerenone-meets-primary-endpoint-in-phase-iii-finearts-hf-cardiovascular-outcomes-study-in-patients-with-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction/\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"** Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. (September 2015). [\\\"Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial\\\"](https://doi.org/10.1001%2Fjama.2015.10081). _JAMA_. **314** (9): 884â€“94\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1001/jama.2015.10081](https://doi.org/10.1001%2Fjama.2015.10081). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26325557](https://pubmed.ncbi.nlm.nih.gov/26325557).`{{cite journal}}`: CS1 maint: overridden setting (link)\",\"description\":\"21. **^** Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. (September 2015). [\\\"Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial\\\"](https://doi.org/10.1001%2Fjama.2015.10081). _JAMA_. **314** (9): 884â€“94\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1001/jama.2015.10081](https://doi.org/10.1001%2Fjama.2015.10081). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [26325557](https://pubmed.ncbi.nlm.nih.gov/26325557).`{{cite journal}}`: CS1 maint: overridden setting (link)\",\"url\":\"https://doi.org/10.1001%2Fjama.2015.10081\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"** Clinical trial number _[NCT02540993](https://www.clinicaltrials.gov/show/NCT02540993)_ for \\\"Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease (FIDELIO-DKD)\\\" at [ClinicalTrials.gov](ClinicalTrials.gov \\\"ClinicalTrials.gov\\\")\",\"description\":\"22. **^** Clinical trial number _[NCT02540993](https://www.clinicaltrials.gov/show/NCT02540993)_ for \\\"Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease (FIDELIO-DKD)\\\" at [ClinicalTrials.gov](ClinicalTrials.gov \\\"ClinicalTrials.gov\\\")\",\"url\":\"https://www.clinicaltrials.gov/show/NCT02540993\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"** Clinical trial number _[NCT02545049](https://www.clinicaltrials.gov/show/NCT02545049)_ for \\\"Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease (FIGARO-DKD)\\\" at [ClinicalTrials.gov](ClinicalTrials.gov \\\"ClinicalTrials.gov\\\")\",\"description\":\"23. **^** Clinical trial number _[NCT02545049](https://www.clinicaltrials.gov/show/NCT02545049)_ for \\\"Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease (FIGARO-DKD)\\\" at [ClinicalTrials.gov](ClinicalTrials.gov \\\"ClinicalTrials.gov\\\")\",\"url\":\"https://www.clinicaltrials.gov/show/NCT02545049\",\"favicon\":\"\"}],\"images\":[],\"fixedIssues\":[{\"criticality\":\"Critical\",\"issueType\":\"Internal Contradiction\",\"problematicText\":\"Drug class| [Potassium-sparing diuretic](Potassium-sparing_diuretic \\\"Potassium-sparing diuretic\\\") ... Finerenone is a [non-steroidal](Non-steroidal \\\"Non-steroidal\\\") [mineralocorticoid receptor antagonist](Mineralocorticoid_receptor_antagonist \\\"Mineralocorticoid receptor antagonist\\\").[7]\",\"explanation\":\"The infobox classifies finerenone as a \\\"Potassium-sparing diuretic,\\\" while the following text describes it as a \\\"non-steroidal mineralocorticoid receptor antagonist.\\\" Although related, this creates inconsistency in terminology, potentially confusing readers on the precise pharmacological classification. Authoritative sources like Drugs.com and FDA label it as a nonsteroidal mineralocorticoid receptor antagonist (nsMRA).\",\"fixedText\":\"Update the infobox Drug class to \\\"Nonsteroidal mineralocorticoid receptor antagonist\\\" to align with the text and standard classifications.\",\"evidenceSource\":\"Ref 7; Drugs.com monograph [](https://www.drugs.com/monograph/finerenone.html)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"used to reduce the risk of kidney function decline, [kidney failure](Kidney_failure \\\"Kidney failure\\\"), cardiovascular death, non-fatal [heart attacks](Heart_attacks \\\"Heart attacks\\\"), and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes.[8]\\\"\",\"explanation\":\"The described medical uses reflect only the original 2021 FDA approval for CKD in T2D. As of July 2025, the FDA has approved an additional indication for reducing the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with symptomatic heart failure and LVEF â‰¥40%, regardless of diabetes or CKD status. This omission renders the uses outdated and incomplete as of October 2025.\",\"fixedText\":\"Expand the medical uses to include both indications: CKD associated with T2D and symptomatic HF with LVEF â‰¥40%. Add a citation for the new indication immediately after the HF uses.\",\"evidenceSource\":\"FDA approval letter [](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215341Orig1s009ltr.pdf)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"\\\"Finerenone was approved for medical use in the United States in July 2021,[8][10] and in the European Union in February 2022.[9]\\\"\",\"explanation\":\"The approval history lacks mention of the expanded US indication approved in July 2025, which is a significant recent development affecting the drug's scope and clinical application.\",\"fixedText\":\"Add to the approval sentence: \\\"and for heart failure in the United States in July 2025\\\" with a new citation.\",\"evidenceSource\":\"FDA approval letter [](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215341Orig1s009ltr.pdf)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency | Missing Information\",\"problematicText\":\"In the United States, finerenone is indicated to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes.[8]\",\"explanation\":\"The US indication is outdated as of July 2025; FDA approved an additional indication for reducing cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure (LVEF â‰¥40%). This expands the scope and affects current medical applicability, making the section incomplete for recency up to October 2025.\",\"fixedText\":\"Add the new FDA-approved indication for heart failure with LVEF â‰¥40%, citing the latest FDA label. Retain original CKD indication with existing citation.\",\"evidenceSource\":\"[8] and FDA label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215341s009lbl.pdf\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"Finerenone may cause electrolyte imbalances.[17] Symptoms that correlate with higher levels of potassium include nausea, weakness, chest pain, and loss of movement.[17] People with lower levels of sodium may experience headaches, confusion, weakness, and feeling off balance.[17]\",\"explanation\":\"The section lacks incidence rates for the electrolyte imbalances, which are essential for assessing the prevalence and risk in an adverse effects section. Official sources provide specific percentages from clinical trials (e.g., hyperkalemia in 14% of patients). Additionally, the symptom lists are incomplete; authoritative sources include more symptoms such as tingly feeling and irregular heartbeats for hyperkalemia, and memory/thinking problems and unsteadiness for hyponatremia.\",\"fixedText\":\"Add incidence rates from clinical data and complete the symptom lists based on standard medical descriptions of these conditions as they relate to the drug's side effects. Cite official sources inline.\",\"evidenceSource\":\"ref 7 (DailyMed FDA label); Drugs.com (ref 17)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[Entire section]\",\"explanation\":\"The section omits other common adverse effects such as hypotension (low blood pressure, incidence 4.6%) and details on monitoring and management of electrolyte imbalances, which are critical for patient safety and clinical guidance. These are standard in adverse effects sections and supported by regulatory labels.\",\"fixedText\":\"Include hypotension as a common adverse effect with incidence, and add information on monitoring potassium levels and dose adjustments to address risks.\",\"evidenceSource\":\"ref 7 (DailyMed); ref 9 (EMA EPAR)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"The efficacy of finerenone to improve kidney and heart outcomes was evaluated in a randomized, multicenter, double-blind, placebo-controlled study\",\"explanation\":\"The section presents this as the primary evaluation but omits earlier development history, including discovery in 2012, phase II trials like ARTS-DN (2015) and ARTS-HF (2014-2015), which are essential for a complete historical timeline in the \\\"History\\\" section. This creates a knowledge gap in temporal context and historical background.\",\"fixedText\":\"Add summary of discovery and key phase II trials with dates and citations to provide historical background.\",\"evidenceSource\":\"[14] BÃ¤rfacker et al. (2012) for discovery; [21] Bakris et al. (2015) for ARTS-DN; [13] Pitt et al. (2015) for ARTS-HF design\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"Results showed that 504 of the 2,833 participants who received finerenone had at least one of the events in the composite endpoint compared to 600 of the 2,841 participants who received a placebo.\",\"explanation\":\"This describes only the FIDELIO-DKD study (unnamed in text) but omits the confirmatory phase III FIGARO-DKD study (completed 2021, results published 2021), which also supported the approval and label. A History section should include both pivotal trials for completeness.\",\"fixedText\":\"Name the study as FIDELIO-DKD and briefly mention FIGARO-DKD with key results and dates.\",\"evidenceSource\":\"[23] ClinicalTrials.gov NCT02545049 for FIGARO-DKD\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"The FDA granted the approval of Kerendia to Bayer Healthcare.\",\"explanation\":\"The section ends with the 2021 approval but fails to include the significant 2025 expansion of indication to heart failure (approved July 14, 2025, for reducing CV death, HF hospitalization, and urgent visits in adults with symptomatic HF and LVEF â‰¥40%), based on FINEARTS-HF trial results (2024). As of October 25, 2025, this is a recent development that updates the drug's history and scope.\",\"fixedText\":\"Add details of the 2025 FDA approval for the new indication, citing the official announcement, to reflect current history.\",\"evidenceSource\":\"[](https://www.bayer.com/en/us/news-stories/fda-approves-kerendia); [20] for FINEARTS-HF results\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"The section only discusses the EU approval process and omits other major jurisdictions.\",\"explanation\":\"The \\\"Legal status\\\" section is incomplete as it exclusively covers the European Union approval, neglecting to mention approvals and regulatory statuses in other key markets like the US, Australia, and Canada, which are referenced in the article's infobox and introduction. This creates a significant knowledge gap in the global regulatory overview, potentially misleading readers on the drug's availability.\",\"fixedText\":\"Add details on approvals in the US (July 2021), Australia (November 2021), and Canada (October 2022), including prescription-only status where applicable, to provide a comprehensive legal status overview consistent with the infobox.\",\"evidenceSource\":\"[8] for US; [2] for Australia; [4] for Canada (approval confirmed as October 2022 via Health Canada).\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Finerenone is sold under the brand names Kerendia and Firialta.[20]\",\"explanation\":\"Citation [20] refers to a Bayer press release about a Phase III clinical trial (FINEARTS-HF) and does not discuss or mention any brand names for finerenone, making it unsupported for this claim.\",\"fixedText\":\"Remove citation [20]. Retain the claim as it is factually correct based on external verification: Kerendia is the primary global brand name (e.g., approved in US, EU, Japan), and Firialta is used in select regions (e.g., Malaysia, Philippines). Add new inline citations to authoritative sources immediately after the claim.\",\"evidenceSource\":\"References section, entry 20\"},{\"criticality\":\"Non-Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"\",\"explanation\":\"The section lists two brand names but does not specify regional availability (e.g., Kerendia in US/EU/Japan, Firialta in parts of Asia), which could provide context without duplicating the \\\"Legal status\\\" section. However, this is not critical as the section's purpose is a simple list of names.\",\"fixedText\":\"Optionally add brief regional notes if expanding, but prioritize brevity; cite sources for each brand.\",\"evidenceSource\":\"Web search results confirming regional branding\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"it is being studied in phase studies designed to assess whether it reduces risk of progression of chronic kidney disease and adverse cardiovascular events in patients with type 2 diabetes. These studies have enrolled more than 13,000 patients with primary completion anticipated in 2020 and 2021.\\\"\",\"explanation\":\"The FIDELIO-DKD and FIGARO-DKD phase III trials completed their primary endpoints in 2020 and 2021, respectively, with results published in peer-reviewed journals demonstrating finerenone's efficacy in reducing CKD progression and CV events, which formed the basis for regulatory approvals. Describing them as ongoing with future completion dates is inaccurate as of October 2025.\",\"fixedText\":\"Revise to state that the phase III trials FIDELIO-DKD and FIGARO-DKD, enrolling over 13,000 patients, were completed in 2020 and 2021, and demonstrated reductions in CKD progression and CV events.\",\"evidenceSource\":\"[](https://www.nejm.org/doi/full/10.1056/NEJMoa2025845) [](https://www.nejm.org/doi/full/10.1056/NEJMoa2110956)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific text; entire section lacks coverage of post-approval research.\",\"explanation\":\"The section omits key developments from the completed pivotal trials' results and subsequent research, including the 2024 FINEARTS-HF trial showing benefits in heart failure with mildly reduced or preserved ejection fraction, and ongoing trials in areas like IgA nephropathy and type 1 diabetes-associated CKD as of 2025. This creates knowledge gaps on the drug's investigational expansion beyond approved uses.\",\"fixedText\":\"Add summary of FIDELIO/FIGARO results with citations, and brief mention of FINEARTS-HF outcomes and select ongoing trials, ensuring no duplication with \\\"Medical uses\\\" section.\",\"evidenceSource\":\"[](https://www.nejm.org/doi/abs/10.1056/NEJMoa2407107) [](https://clinicaltrials.gov/study/NCT07056595)\"}],\"slug\":\"Finerenone\",\"title\":\"Finerenone\",\"content\":\"$1f\",\"description\":\"Finerenone\\n\\n| Attribute | Details |\\n|-----------|---------|\\n| Trade names | Kerendia |\\n| Other names | BAY 94-8862 |\\n| AHFS/Drugs.com | Monograph |\\n| MedlinePlus | a621038 |\\n| License data | US...\",\"metadata\":{\"categories\":[\"Kerendia\"],\"lastModified\":\"1761552900\",\"contentLength\":\"14224\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"50716\",\"recentViews\":\"50716\",\"dailyAvgViews\":1690.5333251953125,\"qualityScore\":1,\"lastViewed\":\"1761884039\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761884039125,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Finerenone\"],\"queryHash\":\"[\\\"page\\\",\\\"Finerenone\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Finerenone\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Finerenone , marketed under the brand name Kerendia among others, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal myocardial infarctions, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes,[8] and to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with symptomatic chronic heart failure and left...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"Kerendia\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Finerenone\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Finerenone\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Finerenone , marketed under the brand name Kerendia among others, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal myocardial infarctions, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes,[8] and to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with symptomatic chronic heart failure and left...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Finerenone\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Finerenone\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:12.900Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Finerenone\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Finerenone , marketed under the brand name Kerendia among others, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal myocardial infarctions, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes,[8] and to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with symptomatic chronic heart failure and left...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="YmZlNGYwYzAtMzczNy00OWJjLWJjNzUtNGIwOWY0NGE1NDhl">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Finerenone\"}]}]\n"])</script></body></html>